Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Safety and Tolerability Study of Ascending Doses of HepaStem in Patients With Cirrhotic and Pre-cirrhotic Non-alcoholic Steato-hepatitis (NASH)

NCT03963921 is registered in ClinicalTrials.gov with Cellaion SA as lead sponsor.

NCT NCT03963921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03963921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Safety and Tolerability Study of Ascending Doses of HepaStem in Patients With Cirrhotic and Pre-cirrhotic Non-alcoholic Steato-hepatitis (NASH)
Lead sponsor
Cellaion SA
Phase
Phase 1/2
Overall status
Completed
Start date
April 9, 2019
Completion date
August 31, 2020
Enrollment
23 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis